Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down to $2.57

Taysha Gene Therapies, Inc. (NASDAQ:TSHAGet Free Report)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $2.57, but opened at $2.50. Taysha Gene Therapies shares last traded at $2.91, with a volume of 578,384 shares traded.

Analysts Set New Price Targets

A number of analysts recently commented on TSHA shares. Jefferies Financial Group reiterated a “buy” rating and set a $8.00 price target (up from $2.00) on shares of Taysha Gene Therapies in a report on Tuesday. Piper Sandler initiated coverage on Taysha Gene Therapies in a research note on Tuesday, April 9th. They issued an “overweight” rating and a $9.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday. JMP Securities restated a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Finally, Chardan Capital boosted their target price on Taysha Gene Therapies from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, March 21st. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Taysha Gene Therapies currently has a consensus rating of “Buy” and a consensus price target of $7.00.

Read Our Latest Research Report on TSHA

Taysha Gene Therapies Stock Performance

The company has a debt-to-equity ratio of 0.54, a quick ratio of 4.08 and a current ratio of 4.08. The company has a market capitalization of $581.63 million, a P/E ratio of -4.48 and a beta of 0.37. The business has a 50 day moving average of $2.61 and a 200-day moving average of $2.11.

Taysha Gene Therapies (NASDAQ:TSHAGet Free Report) last posted its earnings results on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. The business had revenue of $3.41 million for the quarter, compared to analysts’ expectations of $3.70 million. During the same quarter in the previous year, the firm earned ($0.28) earnings per share. On average, sell-side analysts predict that Taysha Gene Therapies, Inc. will post -0.39 EPS for the current fiscal year.

Hedge Funds Weigh In On Taysha Gene Therapies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC boosted its holdings in shares of Taysha Gene Therapies by 328.2% in the 1st quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock worth $53,526,000 after purchasing an additional 14,294,445 shares in the last quarter. StemPoint Capital LP bought a new stake in shares of Taysha Gene Therapies in the 1st quarter valued at about $3,122,000. Quantum Private Wealth LLC lifted its stake in shares of Taysha Gene Therapies by 9.2% in the 1st quarter. Quantum Private Wealth LLC now owns 698,520 shares of the company’s stock valued at $2,005,000 after acquiring an additional 59,000 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Taysha Gene Therapies by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 35,908 shares of the company’s stock valued at $103,000 after acquiring an additional 14,286 shares during the last quarter. Finally, Cannon Global Investment Management LLC bought a new stake in shares of Taysha Gene Therapies in the 1st quarter valued at about $69,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

(Get Free Report)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

Featured Stories

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.